cohorts. SEMS and surgery had a similar rate of complications (35.5% vs 32.5%, p ¼ 0.45) and showed longer time to complications (18m vs 1m, p ¼ 0.004). In patients treated with BV, complications were similar in SEMS and surgery (40% vs 31%, RR 1.28, p ¼ 0.5) and perforation was also similar (13% vs 19%, RR 1.46, p ¼ 0.4). The incidence of perforation in the SEMS group was similar between BV and chemotherapy alone (13% vs 9%, p ¼ 0.2). In patients without systemic therapy, complications were higher in the surgery group compared to SEMS (50% vs 25%, RR 1.34, p ¼ 0.1), also the incidence of perforation (20% vs 6%, RR 1.57, p ¼ 0.2), but not statistically significant. SEMS and surgery showed similar OS (14m vs 15m, p ¼ 0.5). Treatment with BV increased OS in SEMS group (18 months vs 7 months, p ¼ 0.001) and surgery group (20 months vs 4 months, p ¼ 0.001) compared to patients without subsequent medical treatment. In the multivariate analysis, patients treated with subsequent medical treatment showed a statistically significant longer OS [HR 0.43, p ¼ 0.02] and patients who had complications, showed a shorter OS (HR 2.45, CI95% 1.17-5.12, p ¼ 0.01). Conclusions: Bevacizumab-based therapy increased survival in metastatic colon cancer and, was not associated with a higher risk of perforation in patients with SEMS. Emergency surgery and SEMS showed a similar incidence of complications and perforations, with no differences between both strategies in patients treated with BV. Legal entity responsible for the study: Hospital Universitario La Princesa, Instituto de Investigaci on Sanitaria La Princesa. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Background: The standard treatment of Pseudomyxoma Peritonei (PMP) is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) . No consensus was reached on treatment of unresectable or recurrent disease. PMP is considered chemoresistant for its low mitotic index but non-randomized series showed promising results with regimens for gastrointestinal tumors. Metronomic schedules may be preferred for their antiangiogenic and immunomodulatory activity. Methods: We conducted a single center prospective single arm trial. Inclusion criteria were histologically confirmed PMP, unresectable or relapsed after CRS/HIPEC, in progression to surgery or previous treatments. Patients received continuous metronomic capecitabine (625 mg/sqm b.i.d.) plus cyclophosphamide (50 mg/day) until progressive disease, unacceptable toxicity or consent withdrawal. The primary endpoint was progression free survival (PFS); secondary endpoints were disease control rate (DCR), overall survival (OS) and safety profile. Ion TorrentV R next generation sequencing technology (Hot-spot Cancer Panel) was used to characterize molecular profile. Results: 23 consecutive patients were enrolled from April 2015 to October 2017. At a median follow up of 13.5 months, median PFS was 9.5 months and 1-year OS rate 73.7% (95% CI 47.3% -88.3%). No partial or complete responses were observed but DCR was 74% and 22% patients achieved a prolonged disease stability (>13 months). A significant tumor markers reduction (>20%) was seen in 43% patients for CA19.9, 22% for CA125 and 39% for CEA. The safety profile was manageable: 78% patients reported G1/2 drug related adverse events, only 17% G3 and none G4/5. As expected, the main toxicities were anemia, neutropenia, nausea, diarrhea, fatigue and hand foot syndrome. Only 17% patients required capecitabine dose reduction. Molecular profile was available in 15/23 cases: KRAS mutations were found in all cases and GNAS mutations in 47%. Conclusions: Metronomic capecitabine plus cyclophosphamide is an active and well tolerated regimen in unresectable or recurrent PMP, with a safety profile comparing favorably with historical data. Further studies are needed to identify predictive biomarkers for novel treatment strategies. Legal entity responsible for the study: Istituto Nazionale dei Tumori di Milano, Fondazione IRCCS. Background: Primary cancers of the appendix are rare and are frequently diagnosed after surgery for appendicitis. There is no designated staging system or evidence-based guideline for treatment. The staging and treatment of appendiceal adenocarcinoma mirror that of colon cancer. Elevated serum carcinoembryonic antigen (CEA) has been strongly associated with poor prognosis in colorectal cancer, so our study aims to first compare appendiceal cancers with tumors of the ascending colon, and then evaluate the prognostic value of CEA in appendiceal cancers. Methods: We performed a retrospective analysis of all patients (n ¼ 2,614) diagnosed with appendiceal adenocarcinoma from 2004 to 2014 in the National Cancer Institute's Surveillance, Epidemiology and End Results database. All appendiceal cancer patients were designated as either elevated (C1) or normal (C0) based on the pretreatment serum CEA level. We performed univariate and multivariate analyses to compare appendiceal cancer characteristics to tumors of the ascending colon (n ¼ 73,057), then identified independent factors associated with CEA elevation in appendiceal cancers. Results: Upon multivariate analysis, compared to tumors of the ascending colon, appendiceal cancers are significantly more likely (P < 0.05) to have higher stage at diagnosis (OR 2.95, 1.19, 6 .56 for stage 2, 3, and 4). They are less likely to have the CEA test ordered (OR 0.31). Appendiceal cancers are being diagnosed more in recent years (OR 1.90, 2.11, 1.86 for years 2012, 2013, and 2014) while colon cancer incidence is remaining the same. Compared to C0 appendiceal cancers, C1 cancers are more likely to have higher tumor grade (OR 6.56 and 5.50 for grade 2 and 3) and higher overall stage (OR 1.96, 2.44, 9.60 for stage 2, 3, and 4). Conclusions: Though appendiceal cancers are rare, they are increasing in incidence. They are less likely than colorectal cancers to have the CEA test ordered despite CEA elevation odds ratio having no significant difference between the two cancers. Elevated CEA in appendiceal cancers is associated with later stage and higher grade. CEA levels should be checked in all appendiceal cancer patients to assist in the development of treatment strategies. To assess the effect of the KS on OS, multivariate analyses using Cox regression models was performed. The results are expressed as hazard ratios (HR) with 95% CI. Results: Among n ¼ 1,380 CRC patients with available data, the VTE risk (n ¼ 72 events: 5.2%) was similar in the three-and six-month duration arms (5.5% vs. 4.9%) with 0.2% of patients belonging to the high-risk KS group. Rates of VTE were similar in the low-and intermediate-risk groups (4.8% vs. 6.4%). KS did not represent an independent predictive factor for VTE risk, with a low positive predictive value and accuracy (6.4% and 74.1%). Chemotherapy duration was not associated with VTE risk. Also, KS was not associated with OS in multivariate analysis (HR ¼ 0.92, 95% CI, 0.63-1.36; P ¼ 0.68). Conclusions: The use of the KS was not a predictor of VTEs in a low-moderate thromboembolic risk population as CRC. These data did not support the use of KS to estimate the occurrence of VTE during adjuvant chemotherapy and suggest that other assessment risk tools must be evaluated. Legal entity responsible for the study: GISCAD. 
